148 related articles for article (PubMed ID: 2514140)
1. Release of cytokines during generation of lymphokine-activated killer (LAK) cells by IL-2.
Limb GA; Meager A; Woolley J; Wadhwa M; Biggerstaff J; Brown KA; Wolstencroft RA
Immunology; 1989 Dec; 68(4):514-9. PubMed ID: 2514140
[TBL] [Abstract][Full Text] [Related]
2. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
3. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy.
Mier JW; Brandon EP; Libby P; Janicka MW; Aronson FR
J Immunol; 1989 Oct; 143(7):2407-14. PubMed ID: 2528594
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of various cytokines on the generation of rat LAK cells from their purified precursors.
Maghazachi AA
Immunology; 1990 Aug; 70(4):465-72. PubMed ID: 2118478
[TBL] [Abstract][Full Text] [Related]
5. Influence of various cytokines on the induction of lymphokine-activated killer cells.
Bergmann L; Weidmann E; Bungert B; Hechler P; Mitrou PS
Nat Immun Cell Growth Regul; 1990; 9(4):265-73. PubMed ID: 2120581
[TBL] [Abstract][Full Text] [Related]
6. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
[TBL] [Abstract][Full Text] [Related]
7. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
Chong AS; Scuderi P; Grimes WJ; Hersh EM
J Immunol; 1989 Mar; 142(6):2133-9. PubMed ID: 2493506
[TBL] [Abstract][Full Text] [Related]
8. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
9. Mannoprotein-induced anti-U937 cell cytotoxicity in peripheral blood mononuclear cells from uninfected or HIV-infected subjects: role of interferon-gamma and tumor necrosis factor-alpha.
Gomez MJ; Torosantucci A; Quinti I; Testa U; Peschle C; Cassone A
Cell Immunol; 1993 Dec; 152(2):530-43. PubMed ID: 8258154
[TBL] [Abstract][Full Text] [Related]
10. Sequential TNF and TGF-beta regulation of expansion and induction of cytotoxicity in long-term cultures of lymphokine-activated killer cells.
Koberda J; Przepiorka D; Moser RP; Grimm EE
Lymphokine Cytokine Res; 1994 Apr; 13(2):139-45. PubMed ID: 8061115
[TBL] [Abstract][Full Text] [Related]
11. Regulation of lymphokine-activated killer cell induction by human recombinant IL-1 receptor antagonist. Obligate paracrine pathway of IL-1 during lymphokine-activated killer cell induction.
Fujiwara T; Grimm EA
J Immunol; 1992 May; 148(9):2941-6. PubMed ID: 1374105
[TBL] [Abstract][Full Text] [Related]
12. Initial characterization of a lymphokine pathway for the immunologic induction of tumor necrosis factor-alpha release from human peripheral blood mononuclear cells.
Kornbluth RS; Gregory SA; Edgington TS
J Immunol; 1988 Sep; 141(6):2006-15. PubMed ID: 3139748
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of lymphokine-activated T killer cell tumor necrosis factor receptor mRNA transcription, tumor necrosis factor receptor membrane expression, and tumor necrosis factor/lymphotoxin release by IL-1 beta, IL-4, and IL-6 in vitro.
Dett CA; Gatanaga M; Ininns EK; Cappuccini F; Yamamoto RS; Granger GA; Gatanaga T
J Immunol; 1991 Mar; 146(5):1522-6. PubMed ID: 1847164
[TBL] [Abstract][Full Text] [Related]
14. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.
Yang SC; Owen-Schaub LB; Roth JA; Grimm EA
Cancer Res; 1990 Jun; 50(12):3526-32. PubMed ID: 2160321
[TBL] [Abstract][Full Text] [Related]
15. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
Owen-Schaub LB; Gutterman JU; Grimm EA
Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
[TBL] [Abstract][Full Text] [Related]
16. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy.
Heaton KM; Ju G; Grimm EA
Cancer Res; 1993 Jun; 53(11):2597-602. PubMed ID: 8495422
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2 and interferon-gamma recruit different subsets of human peripheral blood monocytes to secrete interleukin-1 beta and tumour necrosis factor-alpha.
Herrmann F; Gebauer G; Lindemann A; Brach M; Mertelsmann R
Clin Exp Immunol; 1989 Jul; 77(1):97-100. PubMed ID: 2504521
[TBL] [Abstract][Full Text] [Related]
18. Cell-associated human retinal pigment epithelium interleukin-8 and monocyte chemotactic protein-1: immunochemical and in-situ hybridization analyses.
Elner VM; Burnstine MA; Strieter RM; Kunkel SL; Elner SG
Exp Eye Res; 1997 Dec; 65(6):781-9. PubMed ID: 9441701
[TBL] [Abstract][Full Text] [Related]
19. Alterations in tumor necrosis factor-alpha, interferon-gamma, and interleukin-6 production by natural killer cell-enriched peripheral blood mononuclear cells in chronic alcoholism: relationship with liver disease and ethanol intake.
Laso FJ; Lapeña P; Madruga JI; San Miguel JF; Orfao A; Iglesias MC; Alvarez-Mon M
Alcohol Clin Exp Res; 1997 Oct; 21(7):1226-31. PubMed ID: 9347083
[TBL] [Abstract][Full Text] [Related]
20. IL-2-activated cord blood mononuclear cells.
Derzic S; Slone V; Sender L
Cytotherapy; 2005; 7(5):408-16. PubMed ID: 16236630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
